Share this Article
Singapore Med J 2013; 54(7): 406-410; http://dx.doi.org/10.11622/smedj.2013143
Use and misuse of thyroid hormone
Topliss DJ, Soh SB
Correspondence: Prof Duncan J Topliss, duncan.topliss@monash.edu
ABSTRACT
Synthetic thyroxine has replaced animal thyroid gland extract as the preferred drug in chronic thyroid hormone replacement. Synthetic thyroxine monotherapy is used to treat overt primary and secondary hypothyroidism, and some cases of subclinical hypothyroidism. In addition, thyroid-stimulating hormone suppressive therapy with thyroxine is a component of the chronic treatment for differentiated thyroid carcinoma. Liothyronine, however, is conventionally for short-term usage, including thyroid hormone withdrawal preparation for radioactive iodine scanning and treatment of differentiated thyroid carcinoma and some cases of myxoedema coma. On very rare occasions where patients are apparently intolerant of or unresponsive to thyroxine, liothyronine may be used chronically. However, there is controversy concerning the use of alternative regimens of thyroid hormone, such as the use of thyroxineliothyronine combination and thyroid extracts. Thyroid hormone has also been misused to promote weight loss and treat ‘symptomatic’ biochemically euthyroid patients. There is insufficient evidence to support the use of thyroid hormone to improve treatment response in depression and severe non-thyroidal illnesses.
Keywords: combination thyroid hormone therapy, liothyronine, thyroid gland extract, thyroxine, use and misuse
Singapore Med J 2013; 54(7): 406-410; http://dx.doi.org/10.11622/smedj.2013143
REFERENCES
| 1. Murray GR. The life history of the first case of myxoedema treated by thyroid extract. Br Med J 1920; 1:359-360. http://dx.doi.org/10.1136/bmj.1.3089.359 | ||||
| 2. Weetman AP. Thyroxine treatment in biochemically euthyroid but clinically hypothyroid individuals. Clin Endocrinol (Oxf) 2002; 57:25-7. http://dx.doi.org/10.1046/j.1365-2265.2002.01561.x | ||||
| 3. Endocrinology Expert Group. Thyroid disorders. Therapeutic guidelines: endocrinology. Version 4. Melbourne: Therapeutic Guidelines Limited, 2009: 103. | ||||
| 4. Abalovich M, Amino N, Babour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2007; 92 (8 Suppl):S1-47. http://dx.doi.org/10.1210/jc.2007-0141 | ||||
| 5. Ashoor G, Maiz N, Rotas M, Jawdat F, Nicolaides KH. Maternal thyroid function at 11 to 13 weeks of gestation and subsequent fetal death. Thyroid 2010; 20:989-93. http://dx.doi.org/10.1089/thy.2010.0058 | ||||
| 6. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341:549-55. http://dx.doi.org/10.1056/NEJM199908193410801 | ||||
| 7. Lazarus JH, Bestwick JP, Channon S, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med 2012; 366:493-501. http://dx.doi.org/10.1056/NEJMoa1106104 | ||||
| 8. Garber JR, Cobin RH, Gharib H, et al. Clinical Practice Guidelines for Hypothyroidism in Adults: Co-sponsored by American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; 11:1-207. | ||||
| 9. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med 2008; 148:832-45. http://dx.doi.org/10.7326/0003-4819-148-11-200806030-00225 | ||||
| 10. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol (Oxf) 1995; 43:55-68. http://dx.doi.org/10.1111/j.1365-2265.1995.tb01894.x | ||||
| 11. Wiersinga WM. Adult hypothyroidism - myxedema coma (Chapter 9 section 9.9). In: Thyroid disease manager [online]. Available at: www.thyroidmanager.org Accessed December 6, 2012. | ||||
| 12. Hylander B, Rosenqvist U. Treatment of myxedema coma – factors associated with fatal outcome. Acta Endocrinol (Copenh) 1985; 108:65-71. | ||||
| 13. Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid 1999; 9:1167-74. http://dx.doi.org/10.1089/thy.1999.9.1167 | ||||
| 14. Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison of placebo with L-thyroxine alone or with carbimazole for the treatment of sporadic nontoxic goitre. Lancet 1990; 336:193-7. http://dx.doi.org/10.1016/0140-6736(90)91730-X | ||||
| 15. Cesareo R, Iozzino M, Isgro MA, Annunziata F, Di Stasio E. Short term effects of levothyroxine treatment in thyroid multinodular disease. Endocr J 2010; 57:803-9. http://dx.doi.org/10.1507/endocrj.K10E-144 | ||||
| 16. Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001; 86:998-1005. http://dx.doi.org/10.1210/jc.86.3.998 | ||||
| 17. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29:76-131. http://dx.doi.org/10.1210/er.2006-0043 | ||||
| 18. Svensson J, Ericsson UB, Nilsson P, et al. Levothyroxine treatment reduces thyroid size in children and adolescents with chronic autoimmune thyroiditis. J Clin Endocrinol Metab 2006; 91:1729-34. http://dx.doi.org/10.1210/jc.2005-2400 | ||||
| 19. McGriff NJ, Csako G, Gourgiotis L, et al. Effects of thyroid hormone suppression on adverse clinical outcomes in thyroid cancer. Ann Med 2002; 34:554-64. http://dx.doi.org/10.1080/078538902321117760 | ||||
| 20. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16:1229-42. http://dx.doi.org/10.1089/thy.2006.16.1229 | ||||
| 21. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-214. http://dx.doi.org/10.1089/thy.2009.0110 | ||||
| 22. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20:135-46. http://dx.doi.org/10.1089/thy.2009.0311 | ||||
| 23. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 2011; 21:1081-125. http://dx.doi.org/10.1089/thy.2011.0087 | ||||
| 24. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006; 91:2592-9. http://dx.doi.org/10.1210/jc.2006-0448 | ||||
| 25. Wiersinga WM. Do we need still more trials on T4 and T3 combination therapy in hypothyroidism? Eur J Endocrinol 2009; 161:955-9. http://dx.doi.org/10.1530/EJE-09-0879 | ||||
| 26. Biondl B, Wartofsky L. Combination therapy with T4 and T3: towards personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab 2012; 97:2256-71. http://dx.doi.org/10.1210/jc.2011-3399 | ||||
| 27. Appelhof BC, Peeters RP, Wiersinga WM, et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy. J Clin Endocrinol Metab 2005: 6296-9. http://dx.doi.org/10.1210/jc.2005-0451 | ||||
| 28. Rees-Jones RW, Rolla AR, Larsen PR. Hormonal content of thyroid replacement preparations. JAMA 1980; 243:549-50. http://dx.doi.org/10.1001/jama.1980.03300320041023 | ||||
| 29. Penny R, Frasier SD. Elevated serum concentrations of triiodothyronine in hypothyroid patients. Values for patients receiving USP thyroid. Am J Dis Child 1980; 134:16-8. | ||||
| 30. DeGroot LJ, Larsen PR, Hennemann G. In Chapter 9, The Thyroid and its Diseases. 6th ed. Philadelphia:Churchill Livingstone, 1995. | ||||
| 31. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000; 160:526-34. http://dx.doi.org/10.1001/archinte.160.4.526 | ||||
| 32. Ebeling PR. Endocrine Society of Australia Position Statement on Dessicated Thyroid or Thyroid Extract [online]. Available at: www.endocrinesociety.org.au Accessed December 6, 2012. | ||||
| 33. Fenwick EH. The diuretic action of fresh thyroid juice. Br Med J 1891; 2:798-9. http://dx.doi.org/10.1136/bmj.2.1606.798 | ||||
| 34. Karmisholt J, Andersen S, Laurberg P. Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxedema. J Clin Endocrinol Metab 2011; 96:E99-103. http://dx.doi.org/10.1210/jc.2010-1521 | ||||
| 35. Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol 2010; 316:165-71. http://dx.doi.org/10.1016/j.mce.2009.06.005 | ||||
| 36. Pearce EN. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes 2012; 19:408-13. | ||||
| 37. Wolman SI, Sheppard H, Fern M, Waterlow JC. The effect of triiodothyronine (T3) on protein turnover and metabolic rate. Int J Obes 1985;9:459-63. | ||||
| 38. Abraham RR, Densem JW, Davies P, Davie MW, Wynn V. The effects of triiodothyronine on energy expenditure, nitrogen balance and rates of weight and fat loss in obese patients during prolonged calorie restriction. Int J Obes 1985; 9:433-42. | ||||
| 39. Brennan MD, Powell C, Kaufman KR, et al. The impact of overt and subclinical hypothyroidism on skeletal muscle. Thyroid 2006; 16:375-80. http://dx.doi.org/10.1089/thy.2006.16.375 | ||||
| 40. Kaptein EM, Beale E, Chan LS. Thyroid hormone therapy for obesity and non-thyroidal illnesses: a systemic review. J Clin Endocrinol Metab 2009; 94:3663-75. http://dx.doi.org/10.1210/jc.2009-0899 | ||||
| 41. Hage MP, Azar ST. The link between thyroid function and depression. J Thyroid Res 2012; 2012:590648 Epub ahead of print. | ||||
| 42. Cooper-Kazaz R. Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008; 11:685-99. http://dx.doi.org/10.1017/S1461145707008206 | ||||
| 43. Garlow SJ, Dunlop BW, Ninan PT, Nemeroff CB. The combination of triidothyronine (T3) and sertaline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res 2012; 46:1406-13. http://dx.doi.org/10.1016/j.jpsychires.2012.08.009 | ||||
| 44. Cooper-Kazaz R, van der Deure WM, Medici M, et al. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Dis 2009; 116:113-6. http://dx.doi.org/10.1016/j.jad.2008.10.019 | ||||
| 45. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illness and low serum thyroxine concentration. J Clin Endocrinol Metab 1986; 63:1-8. http://dx.doi.org/10.1210/jcem-63-1-1 | ||||
| 46. Klemperer JD. Thyroid hormone and cardiac surgery. Thyroid 2002; 12:517-21. http://dx.doi.org/10.1089/105072502760143917 | ||||
| 47. Cooper DK, Novitzky D, Wicomb WN, et al. A review of studies relating to thyroid hormone therapy in brain-dead organ donors. Front Biosci 2009; 1:3750-70. http://dx.doi.org/10.2741/3486 | ||||
| 48. Powner DJ, Hernandez M. A review of thyroid hormone administration during adult donor care. Prog Transplant 2005; 15:202-7. | ||||
| 49. American Thyroid Association statement on "Wilson's syndrome". Posted May 24, 2005 [online]. Available at: www.thyroid.org Accessed December 6, 2012. | ||||
| 50. Mackowiak PA, Wasserman SS, Levine MM. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 1992; 268:1578-80. http://dx.doi.org/10.1001/jama.1992.03490120092034 | ||||